R Squared Ltd Has $310,000 Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX

R Squared Ltd grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 347.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 61,257 shares of the company’s stock after purchasing an additional 47,577 shares during the period. R Squared Ltd’s holdings in Recursion Pharmaceuticals were worth $310,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AlphaQuest LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $36,000. GAMMA Investing LLC boosted its stake in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after purchasing an additional 2,026 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $51,000. ADG Wealth Management Group LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $57,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $6.04 on Friday. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The company has a market cap of $2.62 billion, a PE ratio of -3.39 and a beta of 0.91. The company’s 50-day moving average is $5.18 and its two-hundred day moving average is $5.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business had revenue of $19.10 million for the quarter, compared to analyst estimates of $15.38 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The business’s revenue for the quarter was up 33.3% on a year-over-year basis. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider directly owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.